Vaxcyte (NASDAQ:PCVX) is a biotech company focused on developing vaccines to prevent a wide range of infectious diseases. Drawing on cutting-edge research and technology, Vaxcyte is dedicated to engineering next-generation vaccines that promise higher efficacy, safety, and accessibility. The company's portfolio encompasses several projects, including lead candidates aimed at combating pneumococcal and pertussis diseases. With a strong commitment to public health, Vaxcyte's objective is to significantly reduce the global burden of infectious diseases through innovative vaccination solutions. Their approach combines pioneering science with a strategic vision to address unmet medical needs and protect populations around the world.